Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which limits the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosaminoglycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normalization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS IIIA-affected children. These results support the clinical translation of this approach for the treatment of MPS IIIA and other LSDs with CNS involvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, direct delivery of AAV to the CNS was well tolerated in animal models [185, 186].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Lentiviral vector–mediated transduction of autologous CD34+ HSCs has shown therapeutic efficacy in adrenoleukodystrophy (12), and Authorship note: Virginia Haurigot and Sara Marcó contributed equally to this work.”
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 12×
“Asymmetrical distribution of AAV-neutralizing antibodies across the BBB .”
InfluentialClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 2×
“In vivo gene therapy offers the possibility of a one-time treat-ment for MPS IIIA and other inherited diseases, with the prospect of lifelong beneficial effects (14).”
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
Self-citationInagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Lectin binding by resting and reactive microglia
Streit, W. J., & Kreutzberg, G. W. (1987) · Journal of Neurocytology · doi:10.1007/bf01795308 · Cited by 496
Cord-Blood Transplants from Unrelated Donors in Patients with Hurler's Syndrome
Staba, S. L., Escolar, M. L., Poe, M., Kim, Y., Martin, P. L., Szabolcs, P., Allison-Thacker, J., Wood, S., Wenger, D. A., Rubinstein, P., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032613 · Cited by 478
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377 · cited 2×
“…NAb titers in the CSF did not completely block AAV vector transduction in the brain, a result in contrast to previously published results (66) and in agreement with a recent study that explored CNS transduction following intra-CSF delivery in nonhuman primates with low serum NAb titers (64).”
Streit, W. J. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.11.2212623 · Cited by 375
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Self-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Self-citationAdeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 1×
“…NAb titers in the CSF did not completely block AAV vector transduction in the brain, a result in contrast to previously published results (66) and in agreement with a recent study that explored CNS transduction following intra-CSF delivery in nonhuman primates with low serum NAb titers…”
Krivit, W., Peters, C., & Shapiro, E. G. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199904000-00007 · Cited by 273
Ayuso, E., Mingozzi, F., Montane, J., Leon, X., Anguela, X. M., Haurigot, V, Edmonson, S. A., Africa, L., Zhou, S., High, K. A., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.157 · Cited by 272
Self-citationScallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255 · cited 1×
“…clinical study (NCT01474343, clinicaltrials.gov) was recently initiated in which AAVrh.10 vectors carrying the sulfamidase and sulfatase–modifying 1 ( SUMF1 ) genes are administered to the brain through burr holes, a procedure previously established for other neurodegenerative disorders (22, 23).”
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 2×
“Impor-tantly, at least in the context of hemophilia B, immune responses against the human transgene observed in nonhuman primates did not predict the outcome in humans, as no humoral or cellular immunity against the FIX transgene was documented in clinical trials, even in patients carrying null mutations in the endoge…”
Self-citationDavidoff, A. M., Ng, C. Y. C., Zhou, J., Spence, Y., & Nathwani, A. C. (2003) · Blood · doi:10.1182/blood-2002-09-2889 · Cited by 244 · cited 3×
“We and others have previously reported gender differences in liver transduction by AAV vectors of serotypes 2, 5, 8, and 9 in mice and dogs (33, 38, 53), which are independent of the promoter or mouse strain used (29, 33, 38) and which do not affect the transduction of nonhepatic tissues (29, 38)…”
Li, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225
Buchlis, G., Podsakoff, G. M., Radu, A., Hawk, S. M., Flake, A. W., Mingozzi, F., & High, K. A. (2012) · Blood · doi:10.1182/blood-2011-09-382317 · Cited by 221
Self-citationPassini, M. A., Watson, D. J., Vite, C. H., Landsburg, D. J., Feigenbaum, A. L., & Wolfe, J. H. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.7034-7040.2003 · Cited by 214
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 1×
“NAbs can profoundly impact the efficiency of vector transduction after systemic administration (42–44), and several approaches are currently under investigation to overcome this limitation (45, 46).”
Fu, H., DiRosario, J., Killedar, S., Zaraspe, K., & McCarty, D. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.34 · Cited by 197
Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations
Valstar, M. J., Neijs, S., Bruggenwirth, H. T., Olmer, R., Ruijter, G. J. G., Wevers, R. A., van Diggelen, O. P., Poorthuis, B. J., Halley, D. J., & Wijburg, F. A. (2010) · Annals of Neurology · doi:10.1002/ana.22092 · Cited by 194
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G.-P., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57367 · Cited by 190 · cited 1×
“Terminal galactose has been identified as the primary receptor for AAV9 (30), and the glycan-binding avidity of these vectors determines their in vivo fate (31).”
A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome)
Bhaumik, M., Muller, V. J., Rozaklis, T., Linda, J., Dobrenis, K., Bhattacharyya, R., Wurzelmann, S., Finamore, P., Hopwood, J. J., Walkley, S. U., et al. (1999) · Glycobiology · doi:10.1093/glycob/9.12.1389 · Cited by 189
Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
Wilkinson, F. L., Holley, R. J., Langford-Smith, K. J., Badrinath, S., Liao, A., Langford-Smith, A., Cooper, J. D., Jones, S. A., Wraith, J. E., Wynn, R. F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035787 · Cited by 189
Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs
Federici, T., Taub, J. S., Baum, G. R., Gray, S. J., Grieger, J. C., Matthews, K. A., Handy, C. R., Passini, M. A., Samulski, R. J., & Boulis, N. M. (2012) · Gene Therapy · doi:10.1038/gt.2011.130 · Cited by 168
Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands
Ruijter, G. J. G., Valstar, M. J., van de Kamp, J. M., van der Helm, R. M., Durand, S., van Diggelen, O. P., Wevers, R. A., Poorthuis, B. J. H. M., Pshezhetsky, A. V., & Wijburg, F. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.09.011 · Cited by 164
Lysosomal Storage Diseases and the Blood-Brain Barrier
Begley, D. J., Pontikis, C., & Scarpa, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784705504 · Cited by 148
Fraldi, A., Hemsley, K. M., Crawley, A. C., Lombardi, A., Lau, A. A., Sutherland, L. M., Auricchio, A., Ballabio, A., & Hopwood, J. J. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm223 · Cited by 139
Mingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
Self-citationEllinwood, N. M., Ausseil, J., Desmaris, N., Bigou, S., Liu, S., Jens, J. K., Snella, E. M., Mohammed, E. E., Thomson, C. B., Raoul, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.265 · Cited by 137
Intracerebroventricular Administration of Drugs
Cook, A. M., Mieure, K. D., Owen, R. D., Pesaturo, A. B., & Hatton, J. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.7.832 · Cited by 137
Liu, G., Martins, I., Wemmie, J. A., Chiorini, J. A., & Davidson, B. L. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2936-05.2005 · Cited by 129
A fluorimetric enzyme assay for the diagnosis of sanfilippo disease type A (MPS IIIA)
Karpova, E. A., Voznyi, Y. V., Keulemans, J. L. M., Hoogeveen, A. T., WINCHESTER, B. G., Tsvetkova, I. V., & van Diggelen, O. P. (1995) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01799255 · Cited by 124
Ruzo, A., Marcó, S., García, M., Villacampa, P., Ribera, A., Ayuso, E., Maggioni, L., Mingozzi, F., Haurigot, V., & Bosch, F. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.029 · Cited by 121
Self-citation(2018) · Thieme eBooks · doi:10.1055/b-0038-161979 · Cited by 118
Meyer, A., Kossow, K., Gal, A., Mühlhausen, C., Ullrich, K., Braulke, T., & Muschol, N. (2007) · Pediatrics · doi:10.1542/peds.2007-0282 · Cited by 117
A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type D (MPS IIID)
He, W., Voznyi, Y. V., Boer, A. M., Kleijer, W. J., & van Diggelen, O. P. (1993) · Journal of Inherited Metabolic Disease · doi:10.1007/bf00711508 · Cited by 113
Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA
Crawley, A. C., Gliddon, B. L., Auclair, D., Brodie, S. L., Hirte, C., King, B. M., Fuller, M., Hemsley, K. M., & Hopwood, J. J. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.079 · Cited by 109
Langford-Smith, A., Wilkinson, F. L., Langford‐Smith, K., Holley, R. J., Sergijenko, A., Howe, S. J., Bennett, W. R., Jones, S. A., Wraith, J. E., Merry, C. L. R., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.82 · Cited by 105
Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice
Lau, A. A., Crawley, A. C., Hopwood, J. J., & Hemsley, K. M. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.03.024 · Cited by 89
Bhattacharyya, R., Gliddon, B., Beccari, T., Hopwood, J. J., & Stanley, P. (2001) · Glycobiology · doi:10.1093/glycob/11.1.99 · Cited by 83
Hemsley, K. M., Beard, H., King, B. M., & Hopwood, J. J. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2008.00413.x · Cited by 78
Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations
Souweidane, M. M., Fraser, J. F., Arkin, L. M., Sondhi, D., Hackett, N. R., Kaminsky, S. M., Heier, L., Kosofsky, B. E., Worgall, S., Crystal, R. G., et al. (2010) · Journal of Neurosurgery Pediatrics · doi:10.3171/2010.4.peds09507 · Cited by 66
Glycan Binding Avidity Determines the Systemic Fate of Adeno-Associated Virus Type 9
Shen, S., Bryant, K. D., Sun, J., Brown, S. M., Troupes, A. N., Pulicherla, N., & Asokan, A. (2012) · Journal of Virology · doi:10.1128/jvi.01155-12 · Cited by 63
Ciron, C., Cressant, A., Roux, F., Raoul, S., Cherel, Y., Hantraye, P., Déglon, N., Schwartz, B., Barkats, M., Heard, J.-M., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.155 · Cited by 60
Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs—A proof of principle study
Hemsley, K. M., Norman, E. J., Crawley, A. C., Auclair, D., King, B. M., Fuller, M., Lang, D. L., Dean, C. J., Jolly, R. D., & Hopwood, J. J. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.07.013 · Cited by 60
Ruzo, A., García, M., Ribera, A., Villacampa, P., Haurigot, V., Marcó, S., Ayuso, E., Anguela, X. M., Roca, C., Agudo, J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.220 · Cited by 59
Self-citationGarcia, A. R., DaCosta, J. M., Pan, J., Muenzer, J., & Lamsa, J. C. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.03.003 · Cited by 58
Enzyme replacement reduces neuropathology in MPS IIIA dogs
Crawley, A. C., Marshall, N. R., Beard, H., Hassiotis, S., Walsh, V., King, B. M., Hucker, N., Fuller, M., Jolly, R. D., Hopwood, J. J., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.014 · Cited by 57
Safety Evaluation of Chronic Intrathecal Administration of Idursulfase-IT in Cynomolgus Monkeys
Felice, B. R., Wright, T. L., Boyd, R. B., Butt, M. T., Pfeifer, R. W., Pan, J., Ruiz, J. A., Heartlein, M. W., & Calias, P. (2011) · Toxicologic Pathology · doi:10.1177/0192623311409595 · Cited by 47
Fu, H., DiRosario, J., Lu, K., Muenzer, J., & McCarty, D. M. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1480 · Cited by 41
Donsante, A., Levy, B. K., Vogler, C., & Sands, M. S. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0483-4 · Cited by 38
Tamagawa, K., Morimatsu, Y., Fujisawa, K., Hara, A., & Taketomi, T. (1985) · Brain and Development · doi:10.1016/s0387-7604(85)80008-5 · Cited by 37
Central nervous system therapy for lysosomal storage disorders
Enns, G. M., & Huhn, S. L. (2008) · Neurosurgical Focus · doi:10.3171/foc/2008/24/3-4/e11 · Cited by 35
Hemsley, K. M., & Hopwood, J. J. (2009) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp47118 · Cited by 28
Sanfilippo syndrome type C: A clinicopathological autopsy study of a long-term survivor
Kurihara, M., Kumagai, K., & Yagishita, S. (1996) · Pediatric Neurology · doi:10.1016/0887-8994(96)00083-5 · Cited by 26
Gray, S. J., Kalburgi, S. N., McCown, T. J., & Samulski, R. J. (2013) · Gene Therapy · doi:10.1038/gt.2013.11 · Cited by 2
Research works printed but not linked: 1
- Hemsley, 2009, Int J Clin Pharmacol Ther., 47, S118
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citationAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Self-citationTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
FGF21 gene therapy as treatment for obesity and insulin resistance
Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., Rodó, J., Mallol, C., Garcia, M., León, X., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708791 · Cited by 324
Self-citationGene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Metadata
- Authors
- Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., García-Fructuoso, G., Molas, M., Maggioni, L., Muñoz, S., Motas, S., Ruberte, J., Mingozzi, F., Pumarola, M., & Bosch, F.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Children's Hospital of Philadelphia (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-07-01
- Volume
- 123
- Issue
- 8
- Pages
- 3254-3271
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3726158
- OpenAlex
- W2085717798
- Cited by
- 215
- References
- 69
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 27 · 2023: 9 · 2022: 15 · 2021: 16 · 2020: 17 · 2019: 13 · 2018: 27 · 2017: 16 · 2016: 17 · 2015: 17 · 2014: 28 · 2013: 5
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Funders
- Fundación Ramón Areces
- Generalitat de Catalunya
- Ministerio de Ciencia e Innovación
- MPS España
- Universitat Autònoma de Barcelona
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mucopolysaccharidosis type IIIA, lysosomal storage disease, AAV9, blood-brain barrier, heparan sulfate, glycosaminoglycan accumulation, intracerebroventricular administration, beagle dogs, mouse model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.